TAS-0612, a first-in-class RSK-AKT-S6K inhibitor for the treatment of chemoresistant cancers Nov. 23, 2018
AU-15506, a highly potent, selective inhibitor of CDK12 with oral efficacy in a TNBC model Nov. 22, 2018
Nutlin-based PROTAC knockdowns target protein and upregulate p53, decreasing cancer cell viability Nov. 21, 2018
RSS